


PBS Authority Quick Reference Guide

Ikervis Indication: Severe keratitis in an adult patient with dry eye disease which has not improved despite treatment with tear substitutes.¹



If NO to any PBS criteria for initiation and continuing phase; and YES to Ikervis® indication

Private (non-PBS): Patient is not eligible for PBS. The RRP of Ikervis® is \$81.90 as a non-PBS prescription^

^RRP is a guide only and there is no obligation to comply with recommended retail prices, retailers are free to set their own prices.



How to contact PBS for Authority Required approval

(immediate/real-time assessment)



1800 888 333 (24 hours)



www.servicesaustralia.gov.au/HPOS

Checklist for application PBS/RPBS optometrist prescription PATIENT INFORMATION criber full name criber qualificatio Medicare number Ce na 123456789 ber number Id (if appl First and last name Full residential address int's full CFS grade OSDI score PRESCRIBER INFORMATION Your Prescriber number ne it PBS Authority Prescription Number 2830×0.3 **IKERVIS INFORMATION** PBS item number (12663L) Quantity (30 x 0.3mL units) Number of repeats (max. 5) Ikervis indication Please see the PBS website for more information

PBS Information: Authority Required. Refer to PBS Schedule for full information.

Before prescribing, please review the Approved Product Information available on request to Seqirus Medical Information (1800 642 865) or www.seqirus.com.au/products

This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

MINIMUM PRODUCT INFORMATION: IKERVIS[®] (ciclosporin 0.1% ophthalmic emulsion) **Indication:** Treatment of severe keratitis in adult patients with dry eye disease which has not improved despite treatment with tear substitutes. **Contraindications:** Hypersensitivity to the active substance or any of the excipients; Ocular or peri-ocular malignancies or premalignant conditions; Active or suspected ocular or peri-ocular infection. **Precautions:** Any reversible underlying conditions, not associated with dry eye disease, should be treated prior to initiating IKERVIS[®]; History of ocular herpes; Contact lenses should be removed before instillation of eye drops and re-inserted at wake-up time and careful monitoring of severe keratitis is recommended; Glaucoma – limited experience with IKERVIS[®]. Exercise caution especially with concomitant beta-blockers; Co-administration with eye drops containing corticosteroids may potentiate effects of IKERVIS[®] on the immune system; May affect host defences against local infection and malignancies. **Use in Pregnancy (Category C):** No data available; Not recommended in pregnancy unless the potential benefit to mother outweighs the potential risk to fetus. **Use in Lactation:** Insufficient information on breastfed infants; it is unlikely that sufficient amounts are present in breast milk. A decision must be made to discontinue either IKERVIS[®] or breastfeeding during treatment. **Use in Children:** No data available. **Interactions with other medicines:** No data available. **Adverse Effects:** Common: erythema of eyelid; lacrimation increased; ocular hyperaemia; vision blurred; eyelid oedema; conjunctival hyperaemia; eye pruritus. Very common: eye pain, eye irritation. **Dosage and administration:** The recommended dose is one drop of IKERVIS[®] once daily to be applied to the affected eye(s) at bedtime.

References: 1. Ikervis Product Information. 2. Pharmaceutical Benefits Scheme (https://www.pbs.gov.au).

Seqirus (Australia) Pty Ltd. ABN 66 120 398 067. 63 Poplar Road, Parkville Australia 3052. Seqirus Medical Information: 1800 642 865. Seqirus is a trademark of Seqirus UK Limited or its affiliates. IKERVIS is a registered trademark of Santen S.A.S. and distributed by Seqirus (Australia) Pty Ltd under license from Santen Pharmaceutical Asia Pte Ltd. Date of Preparation: September 2021. ANZ-Iker-21-0051.

